British Journal of Dermatology

Volume 172, Issue 3 p. 563

Commentaries

Treatment of choice in superficial basal cell carcinoma

E.R.M. de Haas, 

E.R.M. de Haas

• [email protected]

Erasmus Medical Center, University Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands

Search for more papers by this author

E.R.M. de Haas, 

E.R.M. de Haas

• [email protected]

Erasmus Medical Center, University Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands

Search for more papers by this author

First published: 16 March 2015

https://doi.org/10.1111/bjd.13653

Citations: 1

No abstract is available for this article.

References

• 1Goldacre B. Bad Pharma. London: Fourth Estate, 2012.
  Google Scholar
• 2Roozeboom MH, Nelemans PJ, Mosterd K et al. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. Br J Dermatol 2015; 172: 739–45.
  10.1111/bjd.13299

  CAS PubMed Web of Science® Google Scholar
• 3Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647–54.
  10.1016/S1470-2045(13)70143-8

  CAS PubMed Web of Science® Google Scholar
• 4Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35–48.
  10.1111/j.1365-2133.2008.08666.x

  CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume172, Issue3

March 2015

Page 563

• References

• Related

• Information

Close Figure Viewer

Previous FigureNext Figure

Caption

Download PDF